Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sayed Wahezi

Physical Medicine & Rehabilitation Fort Wayne, IN Medical Doctor

NPI 1073750741 CMS profile 230711

3898 New Vision Dr, Suite B, Fort Wayne, IN 46845

Open in the dashboard

General payments

$160,554

401 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,025,335 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Sayed Wahezi of Fort Wayne, IN is reported in the CMS Open Payments database as having received $160,554 across 401 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,025,335 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Physical Medicine & Rehabilitation profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $52,457 71
2024 General $36,147 61
2023 General $7,522 41
2022 General $8,896 41
2021 General $27,247 72
2020 General $24,110 48
2019 General $4,174 67

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sayed Wahezi
  • Physical Medicine & Rehabilitation median
  • Middle half of Physical Medicine & Rehabilitation
  • National median

In program year 2025, general payments to Sayed Wahezi were reported at $52,457. Among 4,146 Physical Medicine & Rehabilitation profiles paid that year, the median was $139 and the middle half received between $48 and $410.

Show as a table
Year Sayed Wahezi Physical Medicine & Rehabilitation median Middle half National median
2019 $4,174 $133 $45–$390 $163
2020 $24,110 $88 $29–$272 $114
2021 $27,247 $116 $33–$360 $132
2022 $8,896 $123 $40–$378 $149
2023 $7,522 $131 $43–$396 $160
2024 $36,147 $141 $45–$409 $164
2025 $52,457 $139 $48–$410 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $130,291 270 payments
  2. Trice Medical, Inc. $11,330 11 payments
  3. Vertex Pharmaceuticals Incorporated $7,823 12 payments
  4. Vertos Medical, Inc. $2,504 6 payments
  5. Medtronic, Inc. $2,177 29 payments
  6. Abbott Laboratories $2,062 19 payments
  7. Saluda Medical Americas, Inc. $1,873 6 payments
  8. Relievant Medsystems, Inc. $791 9 payments
  9. Nevro Corp. $268 6 payments
  10. Nalu Medical, Inc. $267 2 payments
  11. Other $1,167 31 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $112,928 61 payments
  2. Consulting Fee $20,873 12 payments
  3. Travel and Lodging $13,766 45 payments
  4. Food and Beverage $12,987 283 payments
Products named General payments · program years 2019–2025
  1. WaveWriter Alpha Prime 16 $27,357 37 payments
  2. WAVEWRITER ALPHA $15,406 13 payments
  3. GENERAL - PAIN MANAGEMENT $14,458 25 payments
  4. General - Therapies $9,785 10 payments
  5. SPECTRA WAVEWRITER Pain Management $9,182 17 payments
  6. SPECTRA WAVEWRITER Pain Management $6,044 4 payments
  7. GENERAL PAIN MANAGEMENT $4,928 63 payments
  8. mild Device Kit $2,244 5 payments
  9. Evoke $1,826 5 payments
  10. Vercise $1,128 7 payments
  11. Other $12,987 185 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 13 drugs

Part D claims

981

Median for Pain Management: 951

Drug cost

$63,456

Median for Pain Management: $26,034

Branded share of claims

24.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Doxepin Hcl Generic 317 $39,130
Diclofenac Sodium Er Diclofenac Sodium Brand 185 $13,920
Pregabalin Generic 43 $2,719
Fentanyl Generic 12 $1,779
Naproxen Sodium Generic 13 $1,315
Gabapentin Generic 97 $928
Duloxetine Hcl Generic 95 $916
Tramadol Hcl Generic 21 $713
Diclofenac Sodium Generic 48 $644
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 43 $504

The 10 drugs with the highest cost, of 13 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 46 billing codes

Paid by Medicare

$36,879

Medicare's payments for the services billed

Medicare patients

116

Average age 71

Services billed

354

83 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 48%
Chronic kidney disease 30%
Depression 29%
Ischemic heart disease 28%
COPD 22%
Cancer 14%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $90
$90 — —
BOTOX
  • AbbVie, Inc. $32
$32 — —
QULIPTA
  • AbbVie, Inc. $16
$16 — —
UBRELVY
  • AbbVie, Inc. $16
$16 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

401 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physical Medicine & Rehabilitation in Indiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record